News
Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in UK and South Africa Trials
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced final efficacy of 96.4% against mild, moderate and severe disease caused...
Drug Research
PsiVac and Lonza Enter a Strategic Agreement for the Process Development and cGMP Manufacturing of Ixovex-1
PsiVac, a subsidiary of Ixogen; a UK biotechnology research and development company focused on the development of new therapeutic cancer treatments for solid tumors,...
News
Altimmune Expands AdCOVID Manufacturing Collaboration with Lonza
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that it has expanded its previously-announced AdCOVID™ manufacturing collaboration with Lonza. Under the expanded agreement, Lonza will...
News
CluePoints Sponsors RBQM Live The Definitive Guide to RBQM for Experts and Beginners
CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software for clinical trials, announced that it is proud to be...
Clinical Trials
TrialScope Welcomes Alexion to Its Growing Clinical Trial Disclosure Community
TrialScope, the global leader in clinical trial disclosure and transparency technology, recently added Alexion to its rapidly expanding roster of customers.
Alexion joins the ranks...
News
Science 37 and Xperiome Partner to Increase the Efficiency and Speed of Rare Disease Studies for Patients and Providers
Science 37, the industry leader in decentralized clinical trials, announced today a partnership with Xperiome, a global, rare disease healthtech company. The partnership further...
Clinical Trials
Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for...
The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa Therapeutics on the announcement...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read